New drug launch sends Lupin shares soaring to record highs! Find out what’s next

New drug launch sends Lupin shares soaring to record highs! Find out what’s next

Lupin Limited, a global pharmaceutical major, has seen its share price reach a 52-week high following the launch of its generic Mirabegron Extended-Release Tablets, 50 mg, in the United States. The approval from the United States Food and Drug Administration (USFDA) has enabled Lupin to introduce a generic equivalent of Myrbetriq Extended-Release Tablets, developed by […]

Zydus Lifesciences gets final FDA approval for Mirabegron generic

Zydus Lifesciences gets final FDA approval for Mirabegron generic

Zydus Lifesciences (previously Cadila Healthcare) said that its US subsidiary Zydus Pharmaceuticals (USA) has secured final approval from the US Food and Drug Administration (FDA) for marketing Mirabegron Extended-Release Tablets USP 25 mg and 50 mg. The product is a generic of Myrbetriq, which has approval for the treatment of overactive bladder (OAB) with symptoms […]

Alembic Pharmaceuticals gets FDA approval for Toviaz generic

Alembic Pharmaceuticals gets FDA approval for Toviaz generic

Alembic Pharmaceuticals said that it has secured tentative approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) for its generic drug product Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. The tentatively approved product is the generic of Pfizer’s Toviaz Extended-Release Tablets, 4 mg and 8 mg. […]

Urovant Sciences acquires licensing for hMaxi-K gene therapy to treat overactive bladder from Ion Channel

Urovant Sciences acquires licensing for hMaxi-K gene therapy to treat overactive bladder from Ion Channel

Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a promising gene therapy, hMaxi-K. This therapy is currently under development as a potential treatment for patients with overactive bladder (OAB) who have not found relief through traditional oral pharmacologic therapies. This comes at a time when there […]